DISTINCTIVE
seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal cancer patIents with ras validated wild typE status (distinctive)
AFLIBERCEPT POST ANTI-EGFR IN CCR
· Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment – interim analysis of DISTINCTIVE trial
Scarica il file
· Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients – a subgroup analysis from the DISTINCTIVE trial
Scarica il file